Business Wire

CA-INGRAM-MICRO

8.6.2021 19:06:08 CEST | Business Wire | Press release

Share
Ingram Micro’s IT Channel Partners Gain an Advantage with “Core to Edge” Advanced Solutions for Securing and Managing the Distributed Enterprise

Ingram Micro Inc. ’s multi-million-dollar investments within its global Advanced Solutions organization are resulting in new and innovative business resources, opportunities, services and solutions for IT channel partners in more than 122 countries. As part of its efforts, the industry leader is also continuing to modernize its processes and systems enabling channel partners to benefit from and provide a more exceptional customer experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005190/en/

“Our global Advanced Solutions organization continues to give our channel partners a clear advantage in the markets they serve locally and globally,” says Paul Bay, executive vice president and president, Global Technology Solutions, Ingram Micro. “We’re continuing to invest in and serve as a business partner to solution providers, as well as Managed Services and cloud providers, giving them more innovative ways to run their businesses better, grow markets faster and do more for their customers. We’ve also made it easier for technology manufacturers, cloud and software companies to have an efficient, high impact sales channel with multiple routes to market worldwide.”

Ingram Micro’s Advanced Solutions is a worldwide organization anchored by eight global Centers of Excellence (COEs) and thousands of specialists and solutions architects spanning 122 countries. The worldwide business engages with more than 180 emerging and established vendor partners and operates throughout Asia Pacific (APAC), North America, Latin America, Europe, Middle East and Africa (EMEA).

Over the last three years, Ingram Micro’s Advanced Solutions organization enabled thousands of midsized and small business channel partners to offer a variety of technology solutions including Artificial Intelligence, Cloud, Data Center, IoT, Security and UCaaS technologies. And, within the last 18 months, the organization has achieved major milestones including:

  • Established an innovative Ingram Micro Financial Solutions’ global team ready to design ways to boost cashflow by allowing businesses to buy cloud and consumption licenses together with technology product to consume technology as an operating expense, and an agile credit organization granting auto-credit increases for loyal Ingram Micro channel partners.
  • A custom program for new and emerging manufacturers or providers of enterprise-grade technology solutions and services, such as its most recent global announcement with UiPath
  • Record growth of nearly 30% with Cybersecurity solutions from more than 80 providers and IT channel ecosystem partners, including the industry’s most valuable Cybersecurity companies , and groundbreaking Ingram Micro software solutions currently under pilot in EMEA.
  • Additions to the Business Transformation Centers in Buffalo, NY and recently launched Center in Singapore, showcasing exclusive Ingram Micro-bundled Advanced Solutions, which include in-house consultative professional experts and services, in addition to proof-of-concept demonstrations for business decision-makers.
  • Debut of the UCC Center of Excellence in EMEA, which served as a lifeline for channel partners across EMEA supplying Unified Communications and UCaaS during the pandemic.
  • Expanded Data Center Managed and Professional Services, which give channel partners an easier way to market, sell and support a full solution stack on premise, hybrid and in the cloud.
  • Launch of Ingram Micro’s IoT Innovation Lab and Virtual Experience team based in Irvine, CA, providing a fast-track to IoT solutions adopted by local governments, healthcare, and manufacturing.
  • Dozens of industry accolades locally, regionally and globally for its excellence in execution including Distributor of the Year and Partner of the Year in 2020 and 2021 .

“Last quarter we had a number of strategic vendors sign new agreements in Latin America, North America and APAC to ensure channel partners have an expert level of support for their solutions,” says Advanced Solutions leader Sabine Howest, vice president, Global Partner Engagement and IoT, Ingram Micro.

Additionally, new investments are being made to enhance Ingram Micro’s expertise across the board and in specific categories including robotics and automation, as well as IoT and Artificial Intelligence.

“We’re assembling an ecosystem of valuable partnerships, combined with experts only Ingram Micro can provide to make it easier for our channel partners to go-to-market in a more agile way with modern technology solutions,” says Howest. “More and more channel partners and providers are using our COEs to build unique, global go-to-market teams and alliances to support their solutions and services. 2020 brought us closer to our partners and providers, together we grew stronger and accomplished more than we ever imagined. This year we’ve set the bar high to invest in our partners and give them an even stronger advantage.”

For more information, Ingram Micro channel partners are encouraged to connect with their sales representatives. Click here to learn more about Ingram Micro Advanced Solutions.

About Ingram Micro

Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/IngramMicroLatinAmericaDivision

https://www.facebook.com/IngramTechSol

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye